ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing klebsiella pneumoniae

Michael R. Jacobs, Caryn E. Good, Andrea M. Hujer, Ayman M. Abdelhamed, Daniel D. Rhoads, Kristine M. Hujer, Susan D. Rudin, T. Nicholas Domitrovic, Lynn E. Connolly, Kevin M. Krause, Robin Patel, Cesar A. Arias, Barry N. Kreiswirth, Laura J. Rojas, Roshan D'Souza, Richard C. White, Lauren M. Brinkac, Kevin Nguyen, Indresh Singh, Derrick E. FoutsDavid Van Duin, Robert A. Bonomo

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Plazomicin was tested against 697 recently acquired carbapenemresistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC50 and MIC90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of>32 mg/liter). Resistance was associated with rmtF-, rmtB-, or armA-encoded 16S rRNA methyltransferases in all except 1 isolate.

Original languageEnglish (US)
Article numbere00012-20
JournalAntimicrobial Agents and Chemotherapy
Volume64
Issue number5
DOIs
StatePublished - May 2020

Keywords

  • Antibiotic resistance
  • Carbapenemase
  • Klebsiella
  • Plazomicin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing klebsiella pneumoniae'. Together they form a unique fingerprint.

Cite this